BIOA Stock — BioAge Labs Inc.: Cash, EV, Pipeline

Share price

$8.06

Market cap

$369.9M

Cash

$318.7M

Enterprise value

$51.2M

Balance sheet

Cash	$318.7M
Debt	$0.0M
Net cash	$318.7M
Enterprise value	$51.2M
Basic shares	45.8M shares
Fully diluted shares	57.2M shares
Fully diluted market cap	$461.1M
Cash per share	$6.96

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading BIOA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 11 - Feb 22	Oral BGE-102	Phase 2	Obesity and Cardiovascular Risk	2H 2026
Dec 13, 2027 - Jan 24, 2028	Oral BGE-102	Phase 2	Diabetic Macular Edema (DME)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

BGE-102

Phase 2 · Active Modality: oral small molecule

Target NLRP3

Indications

cardiometabolic disease with baseline inflammation (QUELL-CV) (Phase 2)
diabetic macular edema (DME) (Phase 1)

Catalysts

— H2 2026
— mid-2026
— mid-2027

Status note Lead product candidate. NLRP3 inhibition; Phase 1 SAD/MAD (April 2026) showed reductions in hsCRP and inflammatory biomarkers. QUELL-CV (160 adults with obesity and hsCRP >3 mg/L, 30/60/90 mg QD vs placebo, 12 weeks) dosed first participant June 2026. DME is first ophthalmology proof-of-concept indication. Company evaluating additional NLRP3 indications.

APJ agonist programs

Preclinical · Active Modality: antibody; small molecule

Target APJ

Partnerships JiKang Therapeutics (option agreement, June 2025, for a novel APJ agonist antibody)

Indications

obesity (Preclinical)

Catalysts

— year-end 2026

Status note APJ agonism programs include a novel APJ agonist antibody (JiKang option) and novel small-molecule APJ agonists (US provisional patent filed). Preclinical obesity models cited by company; first IND intended by year-end 2026.

platform-derived discovery programs

Discovery · Active

Partnerships Eli Lilly and Company (advancing earlier-stage platform-derived programs); Novartis Pharma AG (target discovery collaboration, Dec 2024: up to $20M upfront/research funding, up to $530M milestones, reciprocal milestones and tiered royalties)

Indications

undisclosed (Discovery)

Status note Earlier-stage platform-derived programs in collaboration with Lilly; separate target-discovery collaboration with Novartis investigating mechanisms of aging and exercise biology. No named candidates disclosed.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Oral BGE-102
Lead indication	Obesity and Cardiovascular Risk
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07656727	Phase 2	Active, not recruiting	Sponsor	BIOA	—	Obesity and Cardiovascular Risk	2H 2026
NCT07812090	Phase 2	Recruiting	Sponsor	BIOA	—	Diabetic Macular Edema (DME)	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for BioAge Labs, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Braidwell LP	1,033,129	-167,458	0.94%	2026-08-14
OrbiMed Advisors	752,153	+40,342	0.35%	2026-08-14
Sphera Biotech	213,671	+127,153	0.75%	2026-08-14
Ikarian Capital	200,000	+200,000	0.80%	2026-08-14
ADAR1 Capital Management	0	-135,560	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

BIOA — BioAge Labs Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders